Vistagen Therapeutics Inc (NAS:VTGN)

Q1 2026 Vistagen Therapeutics Inc Earnings Call Transcript

Aug 7, 2025 / 09:00 PM GMT

Release Date Price: $2.73 (-8.08%)

Transcript 10-Q8-K

Key Points

Positve

Vistagen Therapeutics Inc (VTGN) is advancing its lead product candidate, intranasal facidiol, through late phase 3 development for the acute treatment of social anxiety disorder (SAD), addressing a significant unmet need.
The company expects to report top-line data from its Palisade 3 phase 3 trial in Q4 2025, which could be a critical value inflection point.
Vistagen is also advancing its KOL outreach and planning further phase 2 development for other product candidates targeting major depressive disorder and menopausal hot flashes.
The company has a strong cash position with $63.2 million in cash equivalents and marketable securities as of June 30, 2025.
Vistagen has enhanced its study protocols and eligibility criteria, which are expected to improve the quality and reliability of trial outcomes.

Negative

Research and development expenses increased significantly to $11.7 million from $7.6 million year-over-year, reflecting higher investment in clinical programs.
The net loss attributable to common stockholders widened to $15.1 million compared to $10.7 million in the same period last year.
There are ongoing risks and uncertainties associated with the forward-looking statements and clinical trial outcomes.
The company had to terminate a clinical trial site in Pennsylvania due to issues with site conduct and enrollment challenges.
Vistagen faces competition from other companies, such as Euphoria (formerly Bionomics), which is also conducting phase 3 trials for SAD.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VTGN.OQ - VistaGen Therapeutics Inc
Q1 2026 Vistagen Therapeutics Inc Earnings Call
Aug 07, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day everyone and thank you for standing by. Welcome to Vistagen Therapeutics fiscal year 2026 1st quarter corporate update conference call and webcast. Please note that today's call is being recorded.

At this time, I'd like to turn the call over to your host, Mark McPartland, senior Vice President, investor relations at Visageen. Mark, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Justin. Good afternoon, everyone, and welcome to Visigen's fiscal year 2026 1st quarter corporate update conference call and webcast.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.